Depot buprenorphine during COVID-19 in Australia: Opportunities and challenges

Field	Value	Language
dc.contributor.author	Arunogiri, S.	en
dc.contributor.author	Lintzeris, N.	en
dc.date.accessioned	2021-06-02T04:55:26Z
dc.date.available	2021-06-02T04:55:26Z
dc.date.issued	2021
dc.identifier.uri	https://hdl.handle.net/2123/25325
dc.description.abstract	The COVID-19 pandemic has presented challenges for traditional models of opioid use disorder treatment worldwide. Depot buprenorphine became available in Australia shortly before the height of the COVID-19 pandemic. This timing provided us an opportunity to examine the utilization and uptake of depot buprenorphine, and to understand the particular benefits and implementation challenges associated with this new formulation of opioid agonist treatment.	en
dc.language.iso	en	en
dc.rights	Copyright All Rights Reserved	en
dc.subject	COVID-19	en
dc.subject	Coronavirus	en
dc.title	Depot buprenorphine during COVID-19 in Australia: Opportunities and challenges	en
dc.type	Article	en
dc.identifier.doi	10.1016/j.jsat.2020.108221
usyd.faculty	SeS faculties schools::Faculty of Medicine and Health	en

Associated file/s

There are no files associated with this item.